The new year for the Russian pharmaceutical industry did not start that well. In January, Russia dispatched 22 bln RUB worth of pharmaceuticals (dispatch prices, VAT included) to the market, which is in monetary terms 3.4% lower than that of January 2017. The growth rates in physical terms are even worse, with a 7.2% decline and 0.29 bln units. The decline was largely due to over-the-counter drugs, with a 13% decline over the year. The dispatch of the Rx category has risen by 4%, though.
2/22/2018 2017 Rating of Russian Pharmacy Chains
At the beginning of the year, pharmaceutical drug sale in non-pharmaceutical stores was once again one of the central topics for the Russian pharmaceutical industry. The industry professionals made an unambiguous assessment of the initiative, which could have called it quits. However, the regulators had other ideas. In December 2017, a draft federal law was submitted for public discussion.
Among veterinary products, feed supplements led the way in import volume in 2017, with 32.8 mln RUB (free circulation prices). Since 2016, feed supplement import has increased by 6.2% in monetary terms. Veterinary drug import has risen by 7.6% in monetary terms, with the volume amounting to more than 23.8 mln RUB. Veterinary API import shows the best progress with 12.9% and 1.8 bln RUB.
Between January and December 2017, Russia imported 74 bln RUB worth of APIs (free circulation prices plus VAT). Pharmacopoeial APIs take up most of it (97.5%) and contributed to the total import volume in monetary terms, which has risen by 22% in comparison with the same period in 2016. Pharmacopoeial API import has risen by 23% over the year, and imports of technical raw materials have decreased by 5.5%.
In 2017, Russia imported 620.4 bln worth of pharmaceutical drugs (free circulation prices plus VAT), which is 4.4 higher than that of the same period last year. Ready-made drugs has the biggest share, with an 8.6% increase over the year and the total import volume amounting to 524.9 bln RUB. In-bulk products account for 95.5 bln RUB with a 13.9% decrease.
Both December and the whole year showed rather disappointing results for Russian pharmaceutical manufacturers. In 2017, Russia produced around 4.5 bln units of pharmaceuticals, which is only 0.7% higher than that in 2016. In monetary terms, the increase is 6.1%, which is still far behind the growth rates in 2015 and 2016. Russian companies put on the market 333.6 bln RUB worth of pharmaceuticals in 2017 (dispatch prices plus VAT).
Russian export of pharmaceutical drugs is rather unstable, with some unusual destinations. In 2017, North Korea became one of the new export partners for Russia. Between January and November 2017, Russian export of drugs to North Korea increased by 3.7 times in monetary terms (in RUB) and by 5.2 times in physical terms (in units).
Between January and November 2017, 86.3% of all imported ready-made pharmaceuticals from the VED list (in monetary terms) had a lower price than recommended by the State Register. In most cases (60.5% of the volume in monetary terms), the difference did not exceed 10 RUB. The difference is most likely due to the peculiarities of the calculation of actual manufacturer prices, as well as the desire of the companies to insure themselves against exports exceeding the register prices.
By the first 11 months of 2017, the exports, excluding exports to EAEU countries, have amounted to 19 bln RUB (including customs duties), which is only 0.4% higher than that of the same period of 2016 (in RUB). However, the positive dynamics alone is somewhat optimistic. The results between January and October 2017 were much more depressing, with the long-term growth rate amounting to -2.2%.
Between January and November 2017, Russia produced 302 bln RUB worth of pharmaceuticals (dispatch prices, VAT included), which is 5.9% higher than that of the same period last year (in RUB). The progress in physical terms amounts only to 2%, as Russia has manufactured 4.1 bln units of drugs.